Navigation Links
Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice

Summary: Proprietary DNA delivery technology enables sustained Interferon-beta production from muscle cells - reduces atherosclerosis progression in mouse model of heart disease

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Research conducted at Cleveland Clinic and presented today at the American College of Cardiology's 58th Annual Scientific Session showed that a single administration of DNA encoding the anti-inflammatory protein interferon-beta (IFN-beta) using Ichor Medical System's TriGrid Delivery System (TriGrid) reduced the development of plaque formation in a mouse model of atherosclerosis.

"The sustained production of this protein reduced the atherosclerotic lesion size and tissue-damaging inflammation that characterize the blood vessels of these mice with atherosclerosis," said Marc S. Penn, M.D., Ph.D., principal investigator from Cleveland Clinic.

While preliminary, these results broaden the support for the use of the electroporation-based TriGrid as an enabling platform technology to provide continuous endogenous production of therapeutic proteins from a patient's own muscle. Previous studies done in collaboration with Dr. Vince Tuohy's lab at Cleveland Clinic demonstrated that one-time delivery of the IFN-beta gene intramuscularly with the TriGrid in a mouse model of multiple sclerosis (MS), resulted in sustained production of IFN-beta and a similar reduction in the severity of clinical disease as compared to a separate group of mice dosed every other day with recombinant IFN-beta (Molecular Therapy 14(3): 416-422 (2006)). This study suggests that in vivo gene transfer of the IFN-beta gene may provide a convenient and viable alternative to constant life-long dosing of the recombinant form of IFN-beta for patients with MS.

Together, these data demonstrate both the potential therapeutic and economic value of Ichor's technology.

"The TriGrid platform makes treatments like interferon-beta more reasonable because a single administration of the gene using the TriGrid results in consistent production of the therapeutic protein in muscle for extended periods of time resulting in a vastly reduced cost," said Ichor CEO Bob Bernard.

The TriGrid is also being used to enable endogenous protein production for DNA-based treatments of HIV, Hepatitis B and C, malaria, avian flu and various forms of cancer in pre-clinical and clinical trials worldwide.

About Cleveland Clinic

Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Approximately 1,800 full-time salaried physicians and researchers at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2005, there were 2.9 million outpatient visits to Cleveland Clinic. Patients came for treatment from every state and from more than 80 countries. There were nearly 54,000 hospital admissions to Cleveland Clinic in 2005. Cleveland Clinic's Web site address is www.clevelandclinic.org.

About Ichor Medical Systems

Ichor Medical Systems, a privately-held biotech company, is developing products based on the in vivo application of electroporation to enhance intracellular delivery of DNA drugs encoding therapeutic proteins or antigens for vaccines. Ichor's proprietary TriGrid(TM) Delivery System (TriGrid) is the first and only integrated and fully automated system for electroporation-mediated DNA administration. This system allows the site of DNA injection, placement of electrodes, rate of DNA administration and timing of electrical pulse application to be consistent among different operators and patients. As a result, Ichor's TriGrid enables safe, effective and reproducible clinical application of electroporation in a manner capable of supporting development and commercialization of DNA-based products. The Ichor system is currently being used on three continents in a wide range of pre-clinical and clinical studies for potential treatments of melanoma, HIV, Hepatitis B, Avian Flu and Multiple Sclerosis.

Contact

Gable PR: 877-251-3888
Erin Koch
Cell: 619-261-0762
erin@gablepr.com
Tom Gable
Cell: 619-251-3881
tom@gablepr.com


'"/>




Related medicine technology :

1. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
4. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
5. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
6. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. Point of Care Strep Tests Speed Treatment, Lower Costs
9. Rapid HIV Testing Increases Possibility of Treatment
10. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
11. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
Breaking Medicine News(10 mins):